Jingxia Liu

Papers

Total Citations

H-Index

About

Jingxia Liu is a leading biostatistician whose work bridges rigorous statistical methodology with transformative clinical research in oncology. Her primary research areas include the design and analysis of clinical trials, risk-directed therapy, and health outcomes research, with a particular focus on head and neck cancers and thoracic surgery. Dr. Liu’s major contributions are exemplified by her seminal 2019 study on minimally invasive lobectomy, which analyzed national utilization trends, outcomes, and costs—garnering 68 citations and shaping surgical practice for lung cancer patients. More recently, she co-authored a landmark 2024 phase 2 trial demonstrating the long-term efficacy of de-escalated adjuvant therapy for HPV-positive oropharyngeal cancer, a risk-directed approach that promises to reduce treatment toxicity without compromising survival. With a career marked by high-impact collaborations, Dr. Liu’s work has directly influenced evidence-based guidelines and patient care. Her ability to translate complex data into actionable clinical insights has made her an indispensable figure in modern cancer research, earning her recognition as a trusted methodological expert in multi-institutional trials.